Roche Ophthalmology Deal History & Licensing Activity
Roche Ophthalmology is a large pharma headquartered in Switzerland. Over the past three years, Roche Ophthalmology has been involved in 4 licensing and acquisition transactions, with a primary focus on Antibodies (3 deals).
Deals (12mo)
0
Active Trials
12
Top Modality
Antibodies
Focus Area
Gastroenterology
Roche Ophthalmology Pipeline Focus
Therapeutic areas and modalities where Roche Ophthalmology is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Roche Ophthalmology Strategic Signals
Key indicators of Roche Ophthalmology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Roche Ophthalmology's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Gastroenterology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
About Roche Ophthalmology Licensing & Deal Activity
Roche Ophthalmology is a large pharma company based in Switzerland that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Roche Ophthalmology ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Roche Ophthalmology include Gastroenterology (2 deals and trials), Immunology (1 deal and trial), and Rare Disease (1 deal and trial). In terms of modality, Roche Ophthalmology has shown particular interest in antibodies, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Roche Ophthalmology and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Roche Ophthalmology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.